- Home
- About
- 🤖 AskAnzal AI Advisor
- 📅 Book a Call
- Your Account
- My AskAnzal Account
Over 2,000 real rulings — analysed for what they mean to your team. Published every day.
Showing 1914 cases
Complaint alleged a third‑party promotional email for Xarelto omitted contraindications/special warnings (renal impairment) and breached a prior undertaking. PMCPA Panel ruled no…
Complaint alleged Roche sponsorship wasn’t declared prominently from the outset on a partnership website and breached a prior undertaking. PMCPA Panel found…
A BBC radio programme about a Roche-sponsored eye health campaign featured partner interviews without declaring Roche’s sponsorship during the audio. PMCPA ruled…
A UK health professional complained that a BMJ-hosted DuoResp Spiromax ad implied broader licensed use than permitted and relied on footnotes. The…
Allergan challenged Xeomin promotional claims in a BMJ ad, leavepiece and conference stand panels. The Panel ruled some claims misleading about complexing…
A competitor challenged Guerbet’s exhibition claim that Dotarem had the “highest Stability”. Although the claim was considered true, the context could imply…
A GP challenged Pfizer’s Toviaz ads comparing fesoterodine 8mg with tolterodine ER 4mg. The PMCPA ruled the comparative claims misleading and unsubstantiated,…
A dermatologist alleged a Ranbaxy letter implied Co-Cyprindiol contained isotretinoin and erythromycin. The Panel found no breach of Clause 7.2, but said…
A GP complained about large promotional emails sent on Sandoz’s behalf. The Panel found the email was promotional but could not determine…
A Times diabetes supplement funded and editorially controlled by Novo Nordisk included an interview describing liraglutide trial benefits. The PMCPA ruled this…
Pfizer admitted a Lipitor journal ad previously ruled in breach reappeared in Practitioner. Panel found breach of Clause 25 (undertaking). Appeal overturned…
A Lipitor journal ad cited economic modelling that 37% vs 82% would hit cholesterol targets. PMCPA said the bold percentages read as…
Bracco’s Niopam materials used the IMPACT study but omitted key methodological context (pooled secondary endpoints; power/sample size), creating a misleading impression. PMCPA…
A Viramune journal ad promoted awareness of the ArTEN study, which included an unlicensed once-daily nevirapine arm. PMCPA ruled the ad was…
Boehringer’s medical information letter and a “scientific” congress stand were found to promote Pradaxa (dabigatran) for unlicensed indications and include misleading/disparaging statements,…
Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases — ask about precedents, clauses, and how they apply to your situation.
One real case. One key lesson. Every week — free.